Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

ИМЕЕТ ЛИ МЕСТО «ПАРАДОКС ОЖИРЕНИЯ» У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА?

https://doi.org/10.15829/1728-8800-2016-4-75-79

Полный текст:

Аннотация

В представленной  статье описаны результаты клинических исследований по изучению “парадокса ожирения” у пациентов с ишемической болезнью сердца.

Об авторах

О. М. Драпкина
Государственный научноисследовательский центр профилактической медицины, Минздрав России, Москва
Драпкина О. М. — Доктор медицинских наук, профессор, заместитель директора по научной и лечебной работе, руководитель отдела фундаментальных и прикладных аспектов ожирения


Р. Н. Шепель
Государственный научноисследовательский центр профилактической медицины, Минздрав России, Москва
Россия

Младший научный сотрудник отдела.

Тел.: +7 (915) 078-77-54, e-mail: r.n.shepel@mail.ru



С. О. Елиашевич
Государственный научноисследовательский центр профилактической медицины, Минздрав России, Москва
Лаборант-исследователь отдела


Список литературы

1. Trends in adult body–mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population–based measurement studies with 19•2 million participants NCD Risk Factor Collaboration (NCD–RisC). Lancet 2016; 387: 1377–1396.

2. Wong R.J., Chou C., Sinha S.R., Kamal A., Ahmed A. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health 2014; 39: 437–445.

3. Saydah S., Bullard K.M., Cheng Y., Ali M.K., Gregg E.W., Geiss L., Imperatore G. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999–2010. Obesity 2014; 22(8):1888–1895.

4. Masters R.K., Reither E.N., Powers D.A., et al. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am J Public Health 2013; 103: 1895–1901.

5. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53:1925–1932.

6. Lavie C.J., Alpert M.A., Arena R., et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. J Am Coll Cardiol HF 2013; 1: 93–102.

7. Bastien M., Poirier P., Lemieux I., Després J–P. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014; 56: 369–381.

8. Calle E., Thun M., Petrelli J. Body–Mass Index and Mortality in a Prospective Cohort of U.S. Adults N Engl J Med 1999; 341: 1097–1105.

9. Lin S.X., Pi–Sunyer E.X. Prevalence of the metabolic syndrome among US middle–aged and older adults with and without diabetes – a preliminary analysis of the NHANES 1999–2002 data. Ethn Dis 2007; 17(1): 35–39.

10. McNeill A.M., Rosamond W.D., Girman C.J. The metabolic syndrome and 11–year risk of incident cardiovascular disease in the atherosclerosis risk in communities (ARIC) study. Diabetes care 2005; 28(2): 385–390.

11. Willett W.C., Dietz W.H., Colditz G.A. Guidelines for healthy weight. N Engl J Med 1999; 341: 427–434.

12. Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: a 26–year follow–up of participants in the Framingham Heart Study. Circulation.1983; 67: 968–977.

13. Minutello R.M., Chou E.T., Hong M.K., Bergman G., Parikh M., Iacovone F., Wong S.C. Impact of body mass index on in–hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry) Am J Cardiol 2004; 93: 1229–1232.

14. Lavie C.J., Alpert M.A., Arena R., et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. J Am Coll Cardiol HF 2013;1: 93–102.

15. Degoulet P., Legrain M., Réach I. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. 1982; 31(2): 103–110.

16. Hastie C.E., Padmanabhan S., Slack R. Obesity paradox in a cohort of 4,880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31(2): 222–226.

17. Ellis S.G., Elliot J., Horrigan M., Raymond R.E., Howell G.. Low–normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996; 78: 642–646.

18. Gruberg L., Weissman N.J., Waksman R., et al. The impact of obesity on the short–term and long–term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002; 39: 578–584.

19. Romero–Corral A., Montori V.M., Somers V.K. Association of Body weight with total mortality and with cardiovascular events in Coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666–678.

20. Oreopoulos A., McAlister F.A., Kalantar–Zadeh K. The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. Eur Heart J 2009; 30: 2584–2592.

21. Rajamanickam A., Kapadia S., Butler S. Does “The Obesity Paradox” exist for survival after a Percutaneous intervention? J Am Coll Cardiol 2010; 55, Issue 10s1.

22. Uretsky S., Messerli F.H., Bangalore S., et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863–870.

23. Poston W.S., Haddock C.K., Conard M., Spertus J.A. Impact of obesity on disease–specific health status after percutaneous coronary intervention in coronary disease patients.Int J Obes Relat Metab Disord. 2004; 28: 1011–1017.

24. Nikolsky E., Kosinski E., Mishkel G.J., Kimmelstiel C., McGarry T.F., Mehran R., Leon M.B., Russell M.E., Ellis S.G., Stone G.W. Impact of obesity on revascularization and restenosis rates after bare–metal and drug–eluting stent implantation (from the TAXUS–IV trial) Am J Cardiol. 2005; 95:709–715.

25. Akin I., Tölg R., Hochadel M., Bergmann M.W., Khattab A.A., Schneider S., Senges J., Kuck K.H., Richardt G., Nienaber C.A. No evidence of “obesity paradox” after treatment with drug–eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug–Eluting Stent) Registry. JACC Cardiovasc Interv 2012; 5: 162–169.

26. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548–2556.

27. Shibata R., Izumiya Y., Sato K. “Adiponectin protects against the development of systolic dysfunction following myocardial infarction”, Journal of Molecular and Cellular Cardiology 2007; 42 (6): 1065–1074.

28. Maeda N., Takahashi M., Funahashi T. PPAR–ligands increase expression and plasma concentration of adiponectin, an adipose–derived protein. Diabetes 2001; 50: 2094–2099.

29. Tao L., Gao E., Jiao X. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115(11): 1408–1416.

30. Lavie C.J, Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925–1932.

31. Minutello R.M., Chou E.T., Hong M.K., Bergman G., Parikh M., Iacovone F., Wong S.C. Impact of body mass index on in–hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry) Am J Cardiol 2004; 93: 1229–1232.

32. Gruberg L., Weissman N.J., Waksman R., Fuchs S., Deible R., Pinnow E.E., Ahmed L.M., Kent K.M., Pichard A.D., Suddath W.O., et al. The impact of obesity on the short–term and long–term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002; 39: 578–584.

33. Halkin A., Singh M., Nikolsky E., Grines C.L., Tcheng J.E., Garcia E., Cox D.A., Turco M., Stuckey T.D., Na Y, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45: 1397–1405.

34. Strandberg T.E., Strandberg A.Y., Salomaa V.V., Pitkälä K.H., Tilvis R.S., Sirola J., Miettinen T.A. Explaining the obesity paradox: cardiovascular risk, weight change, and mortality during long–term follow–up in men.Eur Heart J 2009; 30: 1720–1727.

35. Sorkin J.D., Muller D.C., Andres R. Longitudinal change in height of men and women: implications for interpretation of the body mass index: the Baltimore Longitudinal Study of Aging. Am J Epidemiol 1999; 150: 969–977.

36. Powell B.D., Lennon R.J., Lerman A., Bell M.R., Berger P.B., Higano S.T., Holmes D.R., Rihal C.S. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003; 91: 472–476.

37. Mohamed–Ali V., Goodrick S., Bulmer K., Holly J.M., Yudkin J.S., Coppack S.W. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999; 277: E971–E975.


Для цитирования:


Драпкина О.М., Шепель Р.Н., Елиашевич С.О. ИМЕЕТ ЛИ МЕСТО «ПАРАДОКС ОЖИРЕНИЯ» У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА? Кардиоваскулярная терапия и профилактика. 2016;15(4):75-79. https://doi.org/10.15829/1728-8800-2016-4-75-79

For citation:


Drapkina O.M., Shepel R.N., Eliashevich S.O. DOES THE “OBESITY PARADOX” REALLY TAKE PLACE IN CORONARY HEART DISEASE? Cardiovascular Therapy and Prevention. 2016;15(4):75-79. (In Russ.) https://doi.org/10.15829/1728-8800-2016-4-75-79

Просмотров: 129


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)